Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
- CEO Christophe Weber to retire from Takeda in June 2026 after 12 years
-
Julie Kim, president of the
U.S. Business Unit, named to succeed Weber after multi-year succession process
“The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber’s remarkable leadership,” said Masami Iijima, chair of the Board of Directors meeting and of the Nomination Committee. “During Christophe’s 12 years of leadership, Takeda has transformed into a competitive, global R&D-driven biopharmaceutical company, with a long-term sustainable business model. We are grateful for his tremendous impact and for his continued leadership at Takeda and support to Julie over the next 18 months. Julie is an outstanding leader who has made significant contributions to the company, notably in leading the
Commenting on the selection process, Mr. Iijima said that “after undergoing a multi-year succession process, the Board determined that Julie Kim is the best leader among a strong pool of both internal and external candidates. The selection process followed by the Nomination Committee and the Board has been thorough and exemplary.”
“For several years, I have worked with the Board to ensure a smooth succession,” said Christophe Weber. “Now is the right time to appoint my successor given our competitive growth outlook, new product launches expected from the second half of 2026 onwards and the anticipated retirement of some external independent directors in the coming years. The Board’s selection of Julie is outstanding. I have worked closely with Julie for the past six years and have witnessed firsthand her values, intellect, grit and dedication to our people and patients.”
“Takeda is a unique company, and I am deeply honored to have been chosen to lead it,” said Julie Kim. “Thanks to Christophe’s phenomenal leadership, Takeda has become a global biopharmaceutical powerhouse with a promising late-stage pipeline. I am excited to guide Takeda through the next phase, together with our exceptional and talented people, while staying true to our strong culture that is rooted in our values and shaped by a heritage of more than 240 years. I want to thank the Board of Directors for their confidence in me. I look forward to working with the Board, Takeda’s executive team and all colleagues to serve and create long-term value for patients, shareholders and society.”
About Christophe Weber
Christophe Weber joined Takeda in April 2014 as chief operating officer. He was named president and representative director in June 2014, and subsequently appointed CEO in April 2015. Under Mr. Weber’s leadership, Takeda has focused on enhancing competitiveness through globalization and R&D transformation, while fostering a diverse and inclusive work environment and reinforcing ethical values and corporate governance.
About Julie Kim
Julie Kim has been the president of the
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
(Attachment)
1. Changes in Appointment and Titles of Representative Directors |
||
Name |
New Title (planned) |
Current Title |
Julie Kim |
Representative Director, President & Chief Executive Officer* |
President, |
Christophe Weber |
Retirement |
Representative Director, President & Chief Executive Officer |
* Subject to election and appointment at the 150th Ordinary General Meeting of Shareholders and Board of Directors meeting in June 2026. |
2. Biography of Newly Appointed Representative Director |
|||
Date of Birth |
Business Experience |
Number of ADSs Held* |
|
June 6, 1970 |
June 2016 |
Joined Shire plc |
95,065 ADSs |
June 2016 |
Head of International Value Demonstration & Access |
||
May 2018 |
Head of Global Hematology Franchise |
||
January 2019 |
Joined Takeda Pharmaceutical Company Limited |
||
January 2019 |
President, Plasma-Derived Therapies Business Unit |
||
April 2022 |
President, |
||
(to present) |
|||
*There are no ordinary shares held as of the filing date. |
3. Effective Date of Changes (planned)
June 2026
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129509380/en/
Takeda Media Relations
Amy Atwood (
amy.atwood@takeda.com
Aya Shishido (
aya.shishido@takeda.com
Takeda Investor Relations
Christopher O’Reilly
Christopher.oreilly@takeda.com
+81 (0) 90-6481-3412
Source: Takeda Pharmaceutical Company Limited